Lack of Serum Bactericidal Activity in Preschool Children Two Years After a Single Dose of Serogroup C Meningococcal Polysaccharide-Protein Conjugate Vaccine
- 1 February 2005
- journal article
- research article
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 24 (2) , 128-131
- https://doi.org/10.1097/01.inf.0000151029.58752.27
Abstract
There is an increased risk of invasive meningococcal disease during the teenage years. A cohort of children vaccinated with a single dose of meningococcal C protein-polysaccharide conjugate (MenC) vaccine in early childhood during the U.K. catch up campaign will enter this age group during the coming decade. The duration of protective immunity against invasive meningococcal C disease provided by this single dose regimen is uncertain. A serum bactericidal titer of Serum bactericidal activity was assessed in 94 children (median age, 4.0 years) at a median time of 1.8 years after vaccination. Of the 94 children, 59 (63%) had a serum bactericidal titer The data from this study add to previous evidence indicating that immunity wanes rapidly after vaccination with serogroup C meningococcal glycoconjugate vaccines in infancy and early childhood. Such observations suggest that booster doses of MenC vaccine may be needed to maintain the successful contribution this vaccine has made to child health in the United Kingdom.Keywords
This publication has 14 references indexed in Scilit:
- Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introductionThe Lancet, 2004
- Validation of Serological Correlate of Protection for Meningococcal C Conjugate Vaccine by Using Efficacy Estimates from Postlicensure Surveillance in EnglandClinical and Vaccine Immunology, 2003
- Immunologic memory in Haemophilus influenzae type b conjugate vaccine failureArchives of Disease in Childhood, 2003
- Antibody Persistence and Immunological Memory at Age 4 Years after Meningococcal Group C Conjugate Vaccination in Children in the United KingdomThe Journal of Infectious Diseases, 2002
- Safety and immunogenicity of meningococcus serogroup C conjugate vaccine administered as a primary or booster vaccination to healthy four-year-old childrenThe Pediatric Infectious Disease Journal, 2002
- Serological Basis for Use of Meningococcal Serogroup C Conjugate Vaccines in the United Kingdom: Reevaluation of Correlates of ProtectionInfection and Immunity, 2001
- Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in EnglandThe Lancet, 2001
- Ability of 3 Different Meningococcal C Conjugate Vaccines to Induce Immunologic Memory after a Single Dose in UK ToddlersThe Journal of Infectious Diseases, 2001
- Safety, Immunogenicity, and Induction of Immunologic Memory by a Serogroup C Meningococcal Conjugate Vaccine in InfantsJAMA, 2000
- Meningococcal Serogroup C Conjugate Vaccine Is Immunogenic in Infancy and Primes for MemoryThe Journal of Infectious Diseases, 1999